Effectiveness and safety profile of tofacitinib and baricitinib in rheumatoid arthritis patients: results from a 24-month real-life prospective study in Southern-Italy
The primary objectives of the study were to evaluate the efficacy and safety of tofacitinib and baricitinib up to 24 months of follow-up in patients with rheumatoid arthritis (RA) treated in Southern Italy. Patients’ data, activity index, and clinimetric scores were collected at baseline (T0), six...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
PAGEPress Publications
2022-12-01
|
| Series: | Reumatismo |
| Subjects: | |
| Online Access: | https://reumatismo.org/index.php/reuma/article/view/1511 |
| _version_ | 1797974544815751168 |
|---|---|
| author | M. Tasso N. Bertolini E. Mostacciuolo S. Passavanti J.M.E. Luppino A. Del Puente R. Peluso F. Santelli R. Scarpa L. Costa F. Caso |
| author_facet | M. Tasso N. Bertolini E. Mostacciuolo S. Passavanti J.M.E. Luppino A. Del Puente R. Peluso F. Santelli R. Scarpa L. Costa F. Caso |
| author_sort | M. Tasso |
| collection | DOAJ |
| description |
The primary objectives of the study were to evaluate the efficacy and safety of tofacitinib and baricitinib up to 24 months of follow-up in patients with rheumatoid arthritis (RA) treated in Southern Italy. Patients’ data, activity index, and clinimetric scores were collected at baseline (T0), six (T6), twelve (T12), and twenty-four (T24) months following treatment initiation. At six, twelve, and twenty-four months, adverse events and treatment cessation were also recorded. Sixty-eight patients (mean age: 62.2±10.9 years; mean RA duration: 15±9.6 years) were enrolled over a period of 12 weeks. At baseline, twenty-four patients (35.3%) were treated with tofacitinib, and forty-four patients (64.7%) were treated with baricitinib. The baseline mean disease activity was moderate as measured by DAS28- ESR (5.0±1.0), DAS 28 CRP (4.69±0.94), and SDAI (26.87±10.73) score. Before beginning JAKinhibs therapy, thirty-two patients (61.8%) were taking bDMARDs, while the remaining thirty-six (38.2%) were bDMARDs-naïve. The 24-month retention rate for JAKinhibs was 91.1%. Six months after beginning treatment with JAKinhibs, a statistically significant improvement was observed in all evaluated activity indices and clinimetric scores. Improvement was confirmed during the 12- and 24-month follow-up evaluations. The positive correlation between baseline-T6 SDAI delta and discontinuation of JAKinhibs (p=0.02) suggests that RA worsening in the first six months may be a predictor of therapy withdrawal. Patients with RA responded favorably to tofacitinib and baricitinib in this prospective, real-world study from a single center in Southern Italy. Efficacy was observed despite an underlying persistent and treatment-resistant disease.
|
| first_indexed | 2024-04-11T04:21:27Z |
| format | Article |
| id | doaj.art-36c0e1477318460fb40c0fe3656af5f6 |
| institution | Directory Open Access Journal |
| issn | 0048-7449 2240-2683 |
| language | English |
| last_indexed | 2024-04-11T04:21:27Z |
| publishDate | 2022-12-01 |
| publisher | PAGEPress Publications |
| record_format | Article |
| series | Reumatismo |
| spelling | doaj.art-36c0e1477318460fb40c0fe3656af5f62022-12-30T13:47:27ZengPAGEPress PublicationsReumatismo0048-74492240-26832022-12-0174310.4081/reumatismo.2022.1511Effectiveness and safety profile of tofacitinib and baricitinib in rheumatoid arthritis patients: results from a 24-month real-life prospective study in Southern-ItalyM. Tasso0N. Bertolini1E. Mostacciuolo2S. Passavanti3J.M.E. Luppino4A. Del Puente5R. Peluso6F. Santelli7R. Scarpa8L. Costa9F. Caso10Rheumatology Unit, Department of Clinical Medicine and Surgery, University of Naples Federico II, NaplesRheumatology Unit, Department of Clinical Medicine and Surgery, University of Naples Federico II, NaplesRheumatology Unit, Department of Clinical Medicine and Surgery, University of Naples Federico II, NaplesRheumatology Unit, Department of Clinical Medicine and Surgery, University of Naples Federico II, NaplesRheumatology Unit, Department of Clinical Medicine and Surgery, University of Naples Federico II, NaplesRheumatology Unit, Department of Clinical Medicine and Surgery, University of Naples Federico II, NaplesRheumatology Unit, Department of Clinical Medicine and Surgery, University of Naples Federico II, NaplesDepartment of Political Science, University of Naples Federico II, NaplesRheumatology Unit, Department of Clinical Medicine and Surgery, University of Naples Federico II, NaplesRheumatology Unit, Department of Clinical Medicine and Surgery, University of Naples Federico II, NaplesRheumatology Unit, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples The primary objectives of the study were to evaluate the efficacy and safety of tofacitinib and baricitinib up to 24 months of follow-up in patients with rheumatoid arthritis (RA) treated in Southern Italy. Patients’ data, activity index, and clinimetric scores were collected at baseline (T0), six (T6), twelve (T12), and twenty-four (T24) months following treatment initiation. At six, twelve, and twenty-four months, adverse events and treatment cessation were also recorded. Sixty-eight patients (mean age: 62.2±10.9 years; mean RA duration: 15±9.6 years) were enrolled over a period of 12 weeks. At baseline, twenty-four patients (35.3%) were treated with tofacitinib, and forty-four patients (64.7%) were treated with baricitinib. The baseline mean disease activity was moderate as measured by DAS28- ESR (5.0±1.0), DAS 28 CRP (4.69±0.94), and SDAI (26.87±10.73) score. Before beginning JAKinhibs therapy, thirty-two patients (61.8%) were taking bDMARDs, while the remaining thirty-six (38.2%) were bDMARDs-naïve. The 24-month retention rate for JAKinhibs was 91.1%. Six months after beginning treatment with JAKinhibs, a statistically significant improvement was observed in all evaluated activity indices and clinimetric scores. Improvement was confirmed during the 12- and 24-month follow-up evaluations. The positive correlation between baseline-T6 SDAI delta and discontinuation of JAKinhibs (p=0.02) suggests that RA worsening in the first six months may be a predictor of therapy withdrawal. Patients with RA responded favorably to tofacitinib and baricitinib in this prospective, real-world study from a single center in Southern Italy. Efficacy was observed despite an underlying persistent and treatment-resistant disease. https://reumatismo.org/index.php/reuma/article/view/1511Rheumatoid ArthritisJAK inhibitorsTofacitinibBaricitinib |
| spellingShingle | M. Tasso N. Bertolini E. Mostacciuolo S. Passavanti J.M.E. Luppino A. Del Puente R. Peluso F. Santelli R. Scarpa L. Costa F. Caso Effectiveness and safety profile of tofacitinib and baricitinib in rheumatoid arthritis patients: results from a 24-month real-life prospective study in Southern-Italy Reumatismo Rheumatoid Arthritis JAK inhibitors Tofacitinib Baricitinib |
| title | Effectiveness and safety profile of tofacitinib and baricitinib in rheumatoid arthritis patients: results from a 24-month real-life prospective study in Southern-Italy |
| title_full | Effectiveness and safety profile of tofacitinib and baricitinib in rheumatoid arthritis patients: results from a 24-month real-life prospective study in Southern-Italy |
| title_fullStr | Effectiveness and safety profile of tofacitinib and baricitinib in rheumatoid arthritis patients: results from a 24-month real-life prospective study in Southern-Italy |
| title_full_unstemmed | Effectiveness and safety profile of tofacitinib and baricitinib in rheumatoid arthritis patients: results from a 24-month real-life prospective study in Southern-Italy |
| title_short | Effectiveness and safety profile of tofacitinib and baricitinib in rheumatoid arthritis patients: results from a 24-month real-life prospective study in Southern-Italy |
| title_sort | effectiveness and safety profile of tofacitinib and baricitinib in rheumatoid arthritis patients results from a 24 month real life prospective study in southern italy |
| topic | Rheumatoid Arthritis JAK inhibitors Tofacitinib Baricitinib |
| url | https://reumatismo.org/index.php/reuma/article/view/1511 |
| work_keys_str_mv | AT mtasso effectivenessandsafetyprofileoftofacitinibandbaricitinibinrheumatoidarthritispatientsresultsfroma24monthreallifeprospectivestudyinsouthernitaly AT nbertolini effectivenessandsafetyprofileoftofacitinibandbaricitinibinrheumatoidarthritispatientsresultsfroma24monthreallifeprospectivestudyinsouthernitaly AT emostacciuolo effectivenessandsafetyprofileoftofacitinibandbaricitinibinrheumatoidarthritispatientsresultsfroma24monthreallifeprospectivestudyinsouthernitaly AT spassavanti effectivenessandsafetyprofileoftofacitinibandbaricitinibinrheumatoidarthritispatientsresultsfroma24monthreallifeprospectivestudyinsouthernitaly AT jmeluppino effectivenessandsafetyprofileoftofacitinibandbaricitinibinrheumatoidarthritispatientsresultsfroma24monthreallifeprospectivestudyinsouthernitaly AT adelpuente effectivenessandsafetyprofileoftofacitinibandbaricitinibinrheumatoidarthritispatientsresultsfroma24monthreallifeprospectivestudyinsouthernitaly AT rpeluso effectivenessandsafetyprofileoftofacitinibandbaricitinibinrheumatoidarthritispatientsresultsfroma24monthreallifeprospectivestudyinsouthernitaly AT fsantelli effectivenessandsafetyprofileoftofacitinibandbaricitinibinrheumatoidarthritispatientsresultsfroma24monthreallifeprospectivestudyinsouthernitaly AT rscarpa effectivenessandsafetyprofileoftofacitinibandbaricitinibinrheumatoidarthritispatientsresultsfroma24monthreallifeprospectivestudyinsouthernitaly AT lcosta effectivenessandsafetyprofileoftofacitinibandbaricitinibinrheumatoidarthritispatientsresultsfroma24monthreallifeprospectivestudyinsouthernitaly AT fcaso effectivenessandsafetyprofileoftofacitinibandbaricitinibinrheumatoidarthritispatientsresultsfroma24monthreallifeprospectivestudyinsouthernitaly |